KRAS mutant allele specific imbalance (MASI) in lung cancer cell lines.Junichi SohNaoki OkumuraWilliam W. LockwoodHiromasa YamamotoHisayuki ShigematsuWei ZhangRaj ChariDavid S. ShamesXiming TangCalum MacAulay
Cancer Cell 前沿发现!肺腺癌类器官模型预测KRAS抑制剂应答! KRAS突变作为肺腺癌中最为常见的致癌基因之一,一直是肿瘤研究领域的焦点问题。因其具有“不可成药靶点”的特征,针对KRAS突变的靶向治疗长期受到广泛关注。 近日,在肺癌研究的最新进展中,中国科学院分子细胞科学卓越创新中心季红斌课题组发表在Cancer Cell的研究...
For instance, PD-L1 expression in KRAS-mutant lung cancer cell lines is regulated by MAPK-dependant transcriptional activity of AP-1 and partially by STAT359. Another study demonstrated a direct association between KRAS mutations and the upregulation of PD-L1, mediated by ERK in human LAC cell...
Bhattacharya S, Socinski M A, Burns T F. KRAS mutant lungcancer: progress thus far on an elusive therapeutic target[J/OL]. ClinTransl Med, 2015, 4(1): 35[2021-07-01]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4678136/...
The G12C inhibitor AZ'8037 has a cytotoxic effect in G12C-mutant lung cancer cells, but G12C & G12V or G12F cell line models showed resistance to the treatment in vitro. Overall, our study provides a novel in vitro evidence of the impact of multiple KRAS mutations on cel- lular...
The overall objective tumor response rate was 51%, indicating that AZD9291 was highly effective in patients with EGFR (T790M) mutant lung cancer whose disease had progressed during previous treatment with EGFR tyrosine kinase inhibitors [71, 72]. JBJ-04-125-02, as an EGFR-mutant allosteric ...
2024年2月22日，中国科学院分子细胞科学卓越创新中心季红斌课题组联合纽约大学医学院Kwok-Kin Wong团队，哈佛医学院丹娜法伯癌症研究所Andrew J. Aguirre团队以及清华大学张奇伟团队在CancerCell上发表文章Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1-mutant lung cancer。该研究发现肺腺鳞癌...
Similarly, A549, H157 and Calu-1 cell lines bearing KRAS mutation were more sensitive to KRA-533 than H292 cells without KRAS mutation (Additional file 1: Figure S1). These findings suggest that KRA-533 may be more suitable to treat mutant KRAS lung cancer. KRA-533 directly binds and ...
1. Burns Timothy F, Borghaei Hossein, Ramalingam Suresh S, et al. Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations.[J] .J Clin Oncol, 2020, 38: 4208-4218. 2. Der C J, Krontiris T G, Cooper G M, Transforming gen...
Inhibition of KRAS(G12D) mutant cell lines The promising results for the inhibitory activity and mutant-selectivity from the ITC and KRAS–CRAF interaction assays motivated us to evaluate the potential anti-cancer effects of TH-Z827. The KRAS G12D mutation is the most prevalent mutation form ...